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Abstract 
Background: Previous studies have demonstrated the feasibility of primary percutaneous coronary intervention 
(PPCI) in carefully selected nonagenarians. Although current guidelines recommend immediate revascularization in 
patients with ST elevation myocardial infarction (STEMI) it remains unclear whether PPCI reduces mortality in nona-
genarians. The objective of this study is to compare mortality in nonagenarians presenting via the PPCI pathway who 
undergo coronary intervention, versus those who are managed medically.
Methods and results: A total of 111 consecutive nonagenarians who presented to our tertiary center via the PPCI 
pathway between July 2013 and December 2018 with myocardial infarction were included. Clinical and angiographic 
details were collected alongside data on all-cause mortality. The final diagnosis was STEMI in 98 (88.3%) and NSTEMI 
in 13 (11.7%). PPCI was performed in 42 (37.8%), while 69 (62.2%) were medically managed. A significant number of 
the medically managed cohort had atrial fibrillation (23.2% vs 2.4% p = 0.003) and presented with a completed infarct 
(43.5% vs 4.8% p = 0.001). Other baseline and clinical variables were well matched in both groups. There was a trend 
towards increased 30-day mortality in the medically managed group (40.6% vs 23.8% p = 0.07). Kaplan Meier survival 
analysis demonstrated a significant difference in survival by 3 years (48.1% vs 21.7% p = 0.01). This was the case even 
when those with completed infarcts were excluded (44.3% vs 14.6%, p = 0.01).
Conclusion: In this series of selected nonagenarians presenting with acute myocardial infarction, those undergoing 
PPCI appeared to have a lower mortality compared to those managed medically.
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Background
The Office for National Statistics reported a 28% rise in 
nonagenarians between 2007 and 2017 in the UK [1]. 
They are however underrepresented in the available lit-
erature on primary percutaneous coronary intervention 
(PPCI) and indeed actively excluded from most rand-
omized control trials. They can be amongst the frailest 
of patients and as such warrant careful consideration on 
whether the risks of coronary intervention outweigh the 
potential benefits.
A review article looking at the pros and cons of any 
coronary intervention in nonagenarians found, when 
carefully selected, the procedure is safe [2]. It suggested, 
rather than using age as a discriminating factor, a more 
detailed assessment of frailty is required. With increas-
ing life-expectancy it is not surprising that registry data 
over the last 10 years indicate Cardiologists are managing 
more nonagenarians invasively. The percentage of inva-
sively managed patients in this population has risen from 
23% of ST elevation myocardial infarction (STEMI) cases 
to 31% [3, 4].
A multicenter retrospective study conducted in France 
recruited 145 nonagenarians treated with PPCI, demon-
strating survival rates at 1 year of 53% [5]. Retrospective 
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studies comparing longer term outcomes between 
patients undergoing PPCI compared to medical man-
agement are sparse [6]. The largest followed 73 patients 
for 2 years and demonstrated a trend towards increased 
survival in the PPCI cohort that did not reach statistical 
significance [7]. The present study seeks to describe our 
experience of managing nonagenarians presenting with 
acute myocardial infarction via the PPCI pathway in a 
large tertiary centre with a large number of PPCI activa-
tions (approximately 1600/year).
Purpose
The primary objective of this study is to compare long 
term survival in nonagenarians managed medically 
against those who underwent PPCI. Secondary analysis 
will focus on factors that predicted 30-day mortality in 
those patients managed with coronary intervention.
Methods
We performed a retrospective single centre study of con-
secutive nonagenarians who arrived at our tertiary centre 
as a PPCI activation between July 2013 and December 
2018. Patients were identified from a prospectively col-
lected database of over 12,000 activations for PPCI. At 
our centre there is no age restriction for PPCI activa-
tion. The inclusion criteria were, symptoms of myo-
cardial ischaemia lasting > 30  min with new significant 
ST-segment or T wave changes or echo evidence of new 
regional wall motion abnormality in patients with left 
bundle branch block or a paced rhythm. Patients were 
divided into those who had immediate PCI and those 
managed medically. Data on demographics, clinical con-
dition on arrival, angiographic details, symptom/door to 
balloon time, 30-day and longer-term survival were man-
ually collected from electronic records.
The third universal definition was used for myo-
cardial infarction [8]. STEMI required ST-segment 
elevation > 1  mm in ≥ 2 contiguous ECG leads. Car-
diogenic shock was defined as a systolic blood pressure 
of < 90  mmHg for a minimum of 30  min or the need to 
use supportive treatments (inotropes/intra-aortic balloon 
pump). Successful PCI was defined as the achievement 
of ≥ TIMI grade 2 flow and residual stenosis of < 30% on 
final angiography. A completed infarct was defined as 
presentation 12  h after symptom onset with associated 
pathological Q waves on ECG. Atrio-ventricular block 
was defined as Mobitz type II or complete heart block.
All patients undergoing PCI were pretreated with dual 
antiplatelet therapy (aspirin administered by paramedics, 
P2Y12 inhibitor immediately pre-procedure) and given 
weight adjusted heparin peri-procedurally to maintain 
an activated clotting time of > 250  s. Radial access and 
drug eluting stents were used in all cases. Arrhythmia on 
admission was documented as new if there was no prior 
clinical history evident. Data on antiplatelet therapy and 
anticoagulation on discharge was collected. Every patient 
had an echo performed during their admission, from 
which LV function was derived.
Statistical analysis
Categorical variables are presented as absolute number 
(percentage); comparisons are made with the chi-squared 
test or Fisher’s exact test as appropriate. Continuous vari-
ables are presented as mean ± standard deviation; com-
parisons are made using the Wilcoxon Signed Rank test. 
Follow-up survival is plotted using the Kaplan–Meier 
method. Additionally, we compared survival to an age 
and sex matched cohort of nonagenarians taken from the 
Office for National Statistics (ONS) life tables. Statistical 
analysis was performed using SAS v9.3 (SAS Institute, 
Cary, NC). A p value of < 0.05 was considered statistically 
significant.
Patient and public involvement
The patients and public were not involved in the design, 
data collection, analysis or preparation of this study.
Results
There were 157 nonagenarian PPCI activations of which 
46 were false activations (29.3%). There were 20 activa-
tions in the first 12  months of this study compared to 
48 in the last 12 months. Of those presenting with true 
myocardial infarction (n = 111, 70.7%) the final diagno-
sis was STEMI in 98 (88.3%) and NSTEMI in 13 (11.7%). 
PPCI was performed in 42 (37.8%), while 69 (62.2%) were 
medically managed (MM). Table  1 summarises baseline 
demographics and clinical status on admission.
No difference in age or sex was seen between those 
managed medically and those undergoing PPCI. There 
was no statistically significant difference between the 
number of patients who lived in a residential or nursing 
home (assisted living 16.7% in PPCI group versus 24.6% 
in the medically managed group p = 0.32). Most patients 
with a previous history of atrial fibrillation (AF) were 
managed medically (23.2% vs 2.4% p = 0.003), otherwise 
no other differences were noted in the comorbidities. 
Interestingly, those who presented with new atrio-
ventricular block were more likely to be managed with 
PCI (19.1% vs 4.4% p = 0.019). No difference was seen 
depending on pre-admission NYHA class. The incidence 
of previous stroke or dementia in this cohort was low and 
equally distributed.
Table 2 summarises left ventricular function, admission 
biochemistry, clinical condition of the patients on admis-
sion and 30-day mortality.
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Both groups had comparable blood test results and 
left ventricular function. A significant proportion of 
the medically managed group presented with a com-
pleted infarct (43.5% vs 4.8% p = 0.001). There was no 
difference in the number of patients who arrived in car-
diogenic shock (9.5% vs 8.7% p > 0.99) or in acute heart 
failure. In 13% of the medically managed cases although 
patients were taken into the lab with the intention to PCI, 
revascularisation was deemed unfeasible due to com-
plex coronary anatomy.  More  patients who presented 
with NSTEMI were managed medically (17.4% vs 2.4% 
p = 0.017). Infarct location determined by ECG did not 
correlate with the decision to perform PPCI.
In total 65% of patients were admitted directly via the 
ambulance service  versus  35% who presented or were 
taken to a peripheral hospital first. Of those that under-
went PPCI only a quarter came from peripheral hospi-
tals with 73.8% being brought directly via the ambulance 
service.
There was a trend towards increased 30-day mortal-
ity in the medically managed group (40.6% vs 23.8% 
p = 0.07). We calculated the BCIS PCI 30-day mortality 
risk score in every patient using admission variables 
and found no significant difference in the mean score 
between groups (22.9% vs 24.0% p = 0.17).
Figure  1 shows the Kaplan Meier chart for all-cause 
mortality.
A statistically significant difference in survival was 
reached by 3 years (48.1% vs 21.7% p = 0.01). Compared 
to the mortality of an age/sex matched population of 
nonagenarians (taken from the ONS life tables), survival 
at 3 years is equivalent in the PPCI cohort and worse in 
those managed medically at 3 years.
A total of 32 patients presented with completed 
infarcts, of which 30 were managed medically. We 
repeated a Kaplan Meier analysis excluding these patients 
to directly compare outcomes in patients with acute 
STEMI in relation to treatment strategy (PCI group 
n = 40, MM group n = 39).
Figure  2 shows the Kaplan Meier chart for all-cause 
mortality, excluding completed infarcts.
The Kaplan Meier curves diverge immediately with 
a statistically significant difference in survival being 
reached by 3 years (44.3% vs 14.6%, p = 0.01).
Table 1 Demographics and co-morbidities
Values in bold demonstrate statistically significant results (p < 0.05)
PPCI primary percutaneous coronary intervention, MM medically managed, e-GFR estimated glomerular filtration rate
± values are mean ± standard deviation. Values in brackets are (%)
Variables PPCI patients (n = 42) MM patients (n = 69) P value
Mean age at operation (years) 92.8 ± 2.5 93.2 ± 2.2 0.22
Female gender, n (%) 21 (50.0) 45 (65.2) 0.11
Assisted living 7 (16.7) 17 (24.6) 0.32
Hypertension 24 (57.1) 45 (65.2) 0.39
Diabetes 5 (11.9) 18 (26.1) 0.07
Chronic kidney disease (e-GFR < 60) 12 (28.6) 25 (36.2) 0.41
History of previous cancer 4 (9.5) 8 (11.6)  > 0.99
History of atrial fibrillation 1 (2.4) 16 (23.2) 0.003
Chronic obstructive pulmonary disease 2 (4.8) 1 (1.5) 0.56
Previous stroke 8 (19.1) 15 (21.7) 0.73
Dementia 1 (2.4) 3 (4.4)  > 0.99
Old bundle branch block 6 (14.3) 6 (8.7) 0.37
Pacemaker/Defibrillator 6 (14.3) 3 (4.4) 0.08
Ex-smoker 14 (33.3) 27 (37.1) 0.54
Current smoker 1 (2.4) 5 (7.3) 0.41
Arrhythmia on admission
New atrial fibrillation 9/41 (22.0) 4/53 (7.5) 0.08
New atrio-ventricular block 8 (19.1) 3 (4.4) 0.019
Pre-admission NYHA class
1 27 (64.3) 39 (56.5) 0.42
2 12 (28.6) 26 (37.7) 0.33
3 2 (4.8) 4 (5.8)  > 0.99
4 1 (2.4) 0 (0) 0.38
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Table  3 summarises the antiplatelet and anticoagula-
tion therapy patients were treated with during admission.
The frequency of single antiplatelet usage was higher 
in the medically managed population. Ticagrelor was 
used in combination with aspirin more frequently in 
the PPCI group (73.8% vs 21.7% p < 0.001). Clopidogrel 
was used more frequently in the medically managed 
group. With those on anticoagulation, triple therapy 
was utilised more often than single antiplatelet plus 
anticoagulation, regardless of whether patients were 
treated with PPCI or medical management.
Table  4. summarises angiographic characteristics in 
the PPCI cohort in relation to 30-day mortality.
There were no differences in symptom-to-balloon 
or door-to-balloon times. Only one patient who pre-
sented as an NSTEMI was taken immediately for 
revascularisation. Cardiogenic shock was associated 
with a higher risk of 30-day mortality. No association 
was seen between infarct location by ECG changes or 
culprit vessel and mortality.
Discussion
Nonagenarians represent an increasing cohort of patients 
as we have seen in our centre over the duration of this 
study. Post mortem studies have shown that coronary 
atherosclerosis is the leading cause of death in this pop-
ulation with as many as 33% dying as a result of acute 
myocardial infarction [9]. The decision to treat very 
elderly patients with STEMI medically is often made due 
to a combination of presumed lack of prognostic benefit 
and perceived risk from invasive management. A large 
Korean study demonstrated that PCI in nonagenarians 
Table 2 Left ventricular function, biochemistry, clinical condition and outcome
Values in bold demonstrate statistically significant results (p < 0.05)
PPCI primary percutaneous coronary intervention, MM medically managed, EF ejection fraction, DGH District general hospital, BCIS British Cardiovascular Intervention 
Society
± values are mean ± standard deviation. Values in brackets are (%)
* Unless otherwise stated
Variables PPCI patients (n = 42)* MM patients (n = 69)* P value
Left ventricular systolic function (n = 38) (n = 61)
Normal (EF > 55%), 5 (11.9) 8 (11.6)  > 0.99
Mildly impaired (EF 46–55%) 6 (14.3) 7 (10.1) 0.55
Moderately impaired (EF 36–45%) 16 (38.1) 21 (30.4) 0.41
Severely impaired (EF ≤ 35%) 11 (26.2) 25 (36.2) 0.27
CK-MB on admission (µg/L) 53.0 ± 89.0 66.9 ± 101.3 0.24
Total Cholesterol (mmol/L), 4.3 ± 1.5 4.2 ± 1.1 0.97
Sodium (mmol/L) 135.9 ± 3.6 135.6 ± 4.1 0.32
Potassium (mmol/L) 4.5 ± 0.5 4.6 ± 0.6  > 0.99
Urea (mmol/L) 9.1 ± 3.3 9.8 ± 4.4 0.93
Creatinine (µmol/L) 109.3 ± 37.9 123.5 ± 72.1 0.54
Glucose (mmol/L) 9.2 ± 3.9 8.5 ± 4.5 0.33
Haemoglobin (g/L) 118.7 ± 16.5 117.7 ± 14.3 0.99
Heart rate on admission (beats/min) 74.3 ± 17.3 79.9 ± 19.0 0.14
Systolic blood pressure (mmHg) 119.5 ± 14.1 120.8 ± 19.1 0.15
Cardiogenic shock 4 (9.5) 6 (8.7)  > 0.99
Completed Infarct 2 (4.8) 30 (43.5)  < 0.001
NSTEMI 1 (2.4) 12 (17.4) 0.017
STEMI 41 (97.6) 57 (82.6) 0.017
Anterior 19 (46.3) 26 (45.6) 0.94
Inferior 17 (41.5) 21 (36.8) 0.64
Lateral 4 (9.8) 7 (12.3) 0.76
Posterior 1 (2.4) 3 (5.3) 0.64
Direct admission via ambulance 31 (73.8) 41 (59.4) 0.12
Transfer from DGH 11 (26.2) 28 (40.6) 0.12
Angiogram Performed 42 (100) 9 (13.0)  < 0.001
30-day mortality 10 (23.8) 28 (40.6) 0.07
BCIS PCI 30-day mortality score 22.9 ± 17.4 24.0 ± 16.6 0.17
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was not associated with more bleeds or fatal in-hospital 
complications [10]. This was reflected in our cohort—
there were no access related complications in any of the 
patients at our centre. Physician bias therefore may be 
leading to fewer nonagenarians receiving appropriate 
invasive therapy. The false activation rate was higher in 
the nonagenarian cohort as compared to overall at our 
centre between 2015 and 2019 (29.3% verses 17.6%). 
Although this does not reach statistical significance there 
Fig. 1 Kaplan Meier for all-cause mortality
Fig. 2 Kaplan Meier for all-cause mortality excluding completed infarcts
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is a clear difference between the groups which reflects 
the complexity of this study population.
In our population, a crude assessment of pre-admis-
sion functional status is reflected via NYHA classifica-
tion, with no difference being seen between groups. 
Many patients were NYHA class I (64.3% in the PPCI 
group, 56.5% in the medically managed) reflecting a very 
healthy subset of nonagenarians. This is further demon-
strated by the relatively low incidence of conditions such 
as dementia. The number of patients who lived in a sup-
ported living facility (nursing or residential home) can 
also be thought of as a surrogate for functional capacity. 
No statistically significant difference was evident between 
the medically managed and PPCI groups. Although not 
validated as a marker of frailty, the BCIS 30-day mortality 
score does demonstrate the pre-interventional risk [11]. 
The similarity in scores suggests patients managed medi-
cally were not significantly more co-morbid. However, 
those with an existing diagnosis of AF were managed 
conservatively more often. This may relate to poor rate 
control or a suspected embolic aetiology for myocardial 
infarction. The potential need for a period of triple ther-
apy (with dual anti-platelets and anti-coagulation) and 
its associated bleeding risk may deter interventionalists 
considering PPCI. Direct oral anticoagulants and their 
relative safety may address this concern in the future 
[12, 13]. It is possible that a small minority of patients in 
the medically managed group had other non-ischaemic 
conditions associated with ST elevation. However, every 
patient included in this study had bedside  echocardio-
grams  confirming regional wall motional abnormalities 
and raised troponins consistent with localised infarct as 
opposed to Tako-Tsubo or pericarditis.
It is interesting to note that a quarter of patients in the 
medically managed group had atrial fibrillation but less 
than 9% were on anticoagulation. This may well suggest 
a perception of high bleeding risk and indeed increased 
frailty in this cohort. It should also be noted, that in this 
nonagenarian cohort, a large proportion of patients were 
Table 3 Antiplatelet/anticoagulation therapy
Values in bold demonstrate statistically significant results (p < 0.05)
PPCI primary percutaneous coronary intervention, MM medically managed, 
Triple therapy aspirin + clopidogrel + anticoagulation









Aspirin only 0 (0) 9 (13.0) 0.013
Aspirin + Clopidogrel 10 (23.8) 32 (46.4) 0.017
Aspirin + Ticagrelor 31 (73.8) 15 (21.7)  < 0.001
Clopidogrel only 1 (2.4) 6 (8.7) 0.25
Anticoagulation agent
Warfarin 1 (2.4) 2 (2.9)  > 0.99
Direct oral anti-coagulation 3 (7.1) 4 (5.8)  > 0.99
Combination therapy
Clopidogrel + Anticoagulation 0 (0) 2 (2.9) 0.53
Triple therapy 4 (9.5) 4 (5.8) 0.47
Table 4 Timing/target vessels in PPCI cohort and 30-day mortality
Values in bold demonstrate statistically significant results (p < 0.05)
PPCI primary percutaneous coronary intervention, NSTEMI non ST elevation myocardial infarction, STEMI ST elevation myocardial infarction, LMS left main stem, RCA 
right coronary artery, LCx left circumflex artery, LAD left anterior descending artery
± values are mean ± standard deviation. Values in brackets are (%)
Variables 30-Day mortality (n = 10) Discharged alive (n = 32) P value
Symptom onset to balloon time (mins) 268.4 ± 234.2 242.9 ± 123.9 0.44
Door to balloon time (mins) 38.2 ± 13.3 37.2 ± 14.4 0.62
Cardiogenic shock 3 (30.0) 1 (3.1) 0.036
NSTEMI 1 (10.0) 0 (0) 0.24
STEMI 9 (90.0) 32 (100) 0.24
Anterior ECG changes 3/9 (33.3) 16 (50.0) 0.47
Inferior ECG changes 6/9 (66.7) 11 (34.4) 0.13
Lateral ECG changes 0 (0) 4 (12.5) 0.56
Posterior ECG changes 0 (0) 1 (3.1)  > 0.99
Culprit vessel
LMS 0 (0) 1 (3.1)  > 0.99
RCA 6 (60.0) 11 (34.4) 0.27
LCx 0 (0) 4 (12.5) 0.56
LAD 4 (40.0) 15 (46.9)  > 0.99
Intermediate 0 (0) 1 (3.1)  > 0.99
Page 7 of 8Meah et al. BMC Cardiovasc Disord           (2021) 21:30  
treated with Clopidogrel (half of all medically managed 
and a quarter of those undergoing PCI). This is perhaps 
not surprising given that the regional protocol advocates 
the use of Ticagrelor as first line therapy unless there are 
cautions or contraindications. Again, this may reflect the 
perceived high bleeding risk.
We have demonstrated a statistically significant differ-
ence in mortality between those managed medically and 
those undergoing  emergency coronary intervention. By 
3  years, nonagenarians who had PPCI had similar sur-
vival to nonagenarians who had not had a myocardial 
infarction. The commonest reason to manage medically 
was late presentation. These patients were deemed to 
have completed infarcts and therefore unlikely to benefit 
from emergency coronary intervention. The large num-
ber of late presenters could be a confounding factor for 
our results. However, repeating the analysis with exclu-
sion of completed infarcts demonstrated no change in 
the mortality benefit seen. Long term survival therefore 
does appear to improve when selected nonagenarians 
with STEMI are treated with coronary intervention.
Cardiogenic shock appears to predict poor prognosis 
in terms of 30-day mortality, as has been described pre-
viously and is to be expected [3]. Procedurally, no dif-
ference was detected between door-to-balloon time or 
symptom-to-balloon time indicating patients undergoing 
PCI all received similar quality care.
Appropriate selection of patients in this cohort is 
clearly important. However, there is little in the avail-
able literature that allows us to use an evidence-based 
approach to selecting the very elderly for PPCI. Accident 
and emergency departments almost certainly hold back 
the frailest patients and equally transfer the strongest, 
but there is a grey area in the middle who may be missing 
out on potentially life prolonging treatment. There is a 
need for validation studies using simple objective tools to 
allow clinicians to grade frailty systematically rather than 
relying on an “end of the bed” test. The Clinical Frailty 
Scale which was developed in Canada and validated in 
a large sample of elderly patients [14] is a mandatory 
assessment of frailty that is used in patients requiring 
left atrial appendage closure [15]. Its use in the acute 
coronary syndrome population has never been tested but 
would be the next logical step.
To our knowledge, this study represents the largest sin-
gle cohort of nonagenarians activating the PPCI pathway. 
Our single centre study confers multiple benefits. The 
UK benefits from publicly available mortality data from 
the Office of National Statistics. Additionally, the single 
centre nature allows us to acquire a very comprehensive 
dataset in terms of morbidity and therapeutic interven-
tion that is often not available in multicentre studies. 
Although selection bias is present, it alone could not 
account for the short- and long-term survival benefit 
seen. As people live longer, the incidence of nonagenar-
ians presenting via the primary PCI pathway is sure to 
rise, our paper adds to the available literature confirming 
that age alone should not exclude anyone from treatment 
[16].
Limitations
This was a retrospective, single centre study. Selection 
bias is inherent as peripheral hospitals are unlikely to 
refer the frailest nonagenarians and ambulance crews 
are unlikely to bring such patients to our centre directly. 
Moreover, the retrospective nature of the study led to 
opportunistic data collection, which increases the prob-
ability of unmeasured confounding factors (we did not 
for instance, have a complete dataset on geriatric assess-
ments of frailty). The medically managed cohort were 
more co-morbid as evidenced by the higher incidence 
of atrial fibrillation and completed infarcts, as such dif-
ferences observed may reflect increased mortality in the 
medically managed group rather than decreased mortal-
ity in the PCI group. We addressed this by repeating sur-
vival analyses excluding the completed infarct and found 
no difference in outcomes, however the size of our cohort 
limited our ability to perform any multivariate analysis 
and therefore the ability to draw firm conclusions. Pro-
spective, randomised studies are unlikely to be conducted 
in this cohort of patients. However larger multi-centre 
studies where validated frailty scores are used, may help 
to better define the risk/benefit ratio. We did not collect 
information on bleeding complications outside of patient 
admission to our tertiary centre, however this has been 
previously covered in the existing literature [10].
Conclusion
We present data that suggests in this series of select 
nonagenarians who presented with acute ST eleva-
tion myocardial infarction to our tertiary center, those 
undergoing primary percutaneous coronary intervention 
appeared to have a lower mortality compared to those 
managed medically.
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